Diamyd Medical 
Welcome,         Profile    Billing    Logout  
 2 Products   42 Diseases  2 Products   3 Trials   208 News 
5 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Diamyd (rhGAD65/alum) / Diamyd Medical
DIAGNODE-3, NCT05018585 / 2021-002731-32: A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes

Recruiting
3
330
Europe, US, RoW
Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Diamyd, Colecalciferol 2000 IU, Divisun 2000 IU, Placebo
Diamyd Medical AB
Type 1 Diabetes Mellitus
12/27
12/27
2014-001323-76: Study to evaluate the tolerability of a combination therapy consisting of GAD-alum (Diamyd®), etanercept and vitamin D in children and adolescents newly diagnosed with type 1 diabetes

Ongoing
2
20
Europe
Diamyd, Enbrel 25 mg pulver och vätska till injektionsvätska, lösning, D-vitamin, Olja ACO 80 IE per droppe, orala droppar, lösning, rhGAD65 formulated in alum (GAD-alum), Suspension for injection, Powder and solvent for solution for injection, Oral drops, Enbrel 25 mg pulver och vätska till injektionsvätska, lösning, D-vitamin, Olja ACO orala droppar, lösning
Linköping University, Linköping University, County Council, Östergötland, Diamyd
Newly diagnosed Type 1 diabetes (within 100 days), Newly Diagnosed Type 1 diabetes (within 100 days), Diseases [C] - Hormonal diseases [C19]
 
 
2019-002692-34: A pilot study to test if a vaccine against autoimmune destruction of the pancreatic insulin-producing cells, when injected directly into a lymph node, is safe and feasible for persons with the LADA (Latent Autoimmune Diabetes in Adults) type of diabetes.

Not yet recruiting
2
15
Europe
rhGAD65-alum, Solution for injection
NTNU, Dept of Clinical and Molecular Medicine, Gastrosenteret, Central Norway Regional Health Authority
Latent autoimmune diabetes in adults (LADA): A common type of diabetes defined by age >30 years, positivity for anti-GAD and no need for insulin the first 6 months after the onset of diabetes., Diseases [C] - Hormonal diseases [C19]
 
 
NCT05683990: Study to Evaluate the Safety and Feasibility of Diamyd® in Individuals at Risk for Type 1 Diabetes

Recruiting
2
16
Europe
Diamyd
Diamyd Medical AB
Diabetes Mellitus, Type 1, Autoimmune Diseases, Prevention
02/25
02/25
NCT05351879: Evaluation of a Booster Administration of GAD-alum (Diamyd®) in Individuals With Type 1 Diabetes

Completed
1/2
6
Europe
GAD-alum (Diamyd) 40 μg/mL
Linkoeping University, Diamyd Medical AB
Diabetes Mellitus, Type 1
08/23
08/23
NP-2 / Diamyd Medical
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Diamyd (rhGAD65/alum) / Diamyd Medical
DIAGNODE-3, NCT05018585 / 2021-002731-32: A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes

Recruiting
3
330
Europe, US, RoW
Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Diamyd, Colecalciferol 2000 IU, Divisun 2000 IU, Placebo
Diamyd Medical AB
Type 1 Diabetes Mellitus
12/27
12/27
2014-001323-76: Study to evaluate the tolerability of a combination therapy consisting of GAD-alum (Diamyd®), etanercept and vitamin D in children and adolescents newly diagnosed with type 1 diabetes

Ongoing
2
20
Europe
Diamyd, Enbrel 25 mg pulver och vätska till injektionsvätska, lösning, D-vitamin, Olja ACO 80 IE per droppe, orala droppar, lösning, rhGAD65 formulated in alum (GAD-alum), Suspension for injection, Powder and solvent for solution for injection, Oral drops, Enbrel 25 mg pulver och vätska till injektionsvätska, lösning, D-vitamin, Olja ACO orala droppar, lösning
Linköping University, Linköping University, County Council, Östergötland, Diamyd
Newly diagnosed Type 1 diabetes (within 100 days), Newly Diagnosed Type 1 diabetes (within 100 days), Diseases [C] - Hormonal diseases [C19]
 
 
2019-002692-34: A pilot study to test if a vaccine against autoimmune destruction of the pancreatic insulin-producing cells, when injected directly into a lymph node, is safe and feasible for persons with the LADA (Latent Autoimmune Diabetes in Adults) type of diabetes.

Not yet recruiting
2
15
Europe
rhGAD65-alum, Solution for injection
NTNU, Dept of Clinical and Molecular Medicine, Gastrosenteret, Central Norway Regional Health Authority
Latent autoimmune diabetes in adults (LADA): A common type of diabetes defined by age >30 years, positivity for anti-GAD and no need for insulin the first 6 months after the onset of diabetes., Diseases [C] - Hormonal diseases [C19]
 
 
NCT05683990: Study to Evaluate the Safety and Feasibility of Diamyd® in Individuals at Risk for Type 1 Diabetes

Recruiting
2
16
Europe
Diamyd
Diamyd Medical AB
Diabetes Mellitus, Type 1, Autoimmune Diseases, Prevention
02/25
02/25
NCT05351879: Evaluation of a Booster Administration of GAD-alum (Diamyd®) in Individuals With Type 1 Diabetes

Completed
1/2
6
Europe
GAD-alum (Diamyd) 40 μg/mL
Linkoeping University, Diamyd Medical AB
Diabetes Mellitus, Type 1
08/23
08/23
NP-2 / Diamyd Medical
No trials found

Download Options